The present invention relates to a medicament for treating or preventing a disease related to orexin receptor, especially orexin type 2 receptor, comprising a new compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient. In more detail, the present invention relates to a medicament for treating or preventing narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc.
The present invention relates to a medicament for treating or preventing a disease related to orexin receptor, especially orexin type 2 receptor, comprising a new compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient. In more detail, the present invention relates to a medicament for treating or preventing narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc.
Mechanism of the liquid-phase catalytic hydrogenolysis on palladium/carbon of cyclohexene epoxides
作者:Georges C. Accrombessi、Patrick Geneste、Jean-Louis Olive、Andre A. Pavia
DOI:10.1021/jo01309a014
日期:1980.10
Novel Catalytic Kinetic Resolution of Racemic Epoxides to Allylic Alcohols
作者:Arnaud Gayet、Sophie Bertilsson、Pher G. Andersson
DOI:10.1021/ol025983e
日期:2002.10.1
[formula: see text] The kineticresolution of racemic epoxides via catalytic enantioselective rearrangement to allylicalcohols was investigated. Using the Li-salt of (1S,3R,4R)-3-(pyrrolidinyl)methyl-2-azabicyclo [2.2.1] heptane 1 as catalyst allowed both epoxides and allylicalcohols to be obtained in an enantioenriched form.